Navigating the road toward optimal initial therapy for chronic myeloid leukemia.

@article{Okimoto2011NavigatingTR,
  title={Navigating the road toward optimal initial therapy for chronic myeloid leukemia.},
  author={Ross A. Okimoto and Richard A. Van Etten},
  journal={Current opinion in hematology},
  year={2011},
  volume={18 2},
  pages={89-97}
}
PURPOSE OF REVIEW Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) and are now widely accepted as the initial therapy of choice in this disease, supplanting interferon and allogeneic stem cell transplantation. There are currently three drugs approved by the US Food and Drug Administration (FDA) for front-line treatment of CML: imatinib, nilotinib, and dasatinib. A fourth drug, bosutinib, may also win FDA approval in 2011. The goal of this… CONTINUE READING
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…